Treating HIV/HCV-Coinfected Patients

A sofosbuvir/ribavirin combination cured infections with hepatitis C virus genotypes 1 through 4 in 84% to 89% of HIV-coinfected patients.

Interferon-based regimens have excessive toxicity and decreased efficacy in patients coinfected with HIV and hepatitis C virus (HCV). New direct-acting anti-HCV drugs, including sofosbuvir, have shown efficacy in this setting, but data are limited. Results from the nonrandomized, open-label PHOTON-2 study have just been published.

In this industry-funded, phase III trial, investigators treated 275 HIV/HCV-coinfected adults in seven European countries with daily sofosbuvir and twice-daily weight-adjusted ribavirin. Sustained virologic response rates 12 weeks following therapy were 85%, 88%, 89%, and 84% for participants with genotype 1, 2, 3, or 4 HCV, respectively. Most treatment failures were due to side effects and patient issues unrelated…

Reviewing Author

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Helmut Albrecht, MD

Disclosures

Grant / Research supportHealth Resources and Services Administration; Centers for Disease Control and Prevention

Leadership positions in professional societiesColumbia Medical Society; South Carolina Infectious Diseases Society

Treating HIV/HCV-Coinfected Patients

Topics

Reviewing Author